caficrestat

Also Known As:

(8-oxo-7-((5-(trifluoromethyl)-1,3-benzothiazol-2-yl)methyl)-7,8- dihydropyrazino(2,3-d)pyridazin-5-yl)acetic acid; 7,8-dihydro-8-oxo-7-((5-(trifluoromethyl)-2-benzothiazolyl)methyl)pyrazino(2,3-d)pyridazine-5-acetic acid; AT-001; AT001

Networked: 5 relevant articles (3 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzothiazoles: 40
      - caficrestat: 5

Experts

1.	Fishman, Glenn: 1 article (11/2021)
2.	Gaztanaga, Juan: 1 article (11/2021)
3.	Katz, Stuart D: 1 article (11/2021)
4.	Perfetti, Riccardo: 1 article (11/2021)
5.	Ramasamy, Ravichandran: 1 article (11/2021)
6.	Schendelman, Shoshana: 1 article (11/2021)
7.	Schmidt, Ann Marie: 1 article (11/2021)
8.	Thangavelu, Karthinathan: 1 article (11/2021)
9.	Chu, Chae: 1 article (07/2020)
10.	Coyle, Justin: 1 article (07/2020)

Related Diseases

1.	COVID-19 11/01/2021 - "While the observed trend did not reach statistical significance, the present study provides the rationale for investigating potential benefit of AT-001 in COVID 19 affected patients in future studies." 01/01/2023 - "AT-001, an AR inhibitor, is now being tested in COVID-19 to see how safe and effective it reduces inflammation and cardiac damage. " 11/01/2021 - "In hospitalized patients with COVID-19 and co-morbid diabetes mellitus and heart disease, treatment with AT-001 was safe and well tolerated. " 11/01/2021 - "We hypothesized that aldose reductase inhibition with AT-001 might reduce viral inflammation and risk of adverse outcomes in diabetic patients with COVID-19. " 11/01/2021 - "We conducted an open-label prospective phase 2 clinical trial to assess safety, tolerability and efficacy of AT-001 in patients hospitalized with COVID-19 infection, history of diabetes mellitus and chronic heart disease. "
2.	Infections 11/01/2021 - "We conducted an open-label prospective phase 2 clinical trial to assess safety, tolerability and efficacy of AT-001 in patients hospitalized with COVID-19 infection, history of diabetes mellitus and chronic heart disease. " 11/01/2021 - "A pilot open-label study of aldose reductase inhibition with AT-001 (caficrestat) in patients hospitalized for COVID-19 infection: Results from a registry-based matched-control analysis."
3.	Inflammation (Inflammations) 01/01/2023 - "AT-001, an AR inhibitor, is now being tested in COVID-19 to see how safe and effective it reduces inflammation and cardiac damage. " 11/01/2021 - "We hypothesized that aldose reductase inhibition with AT-001 might reduce viral inflammation and risk of adverse outcomes in diabetic patients with COVID-19. "
4.	Diabetic Cardiomyopathies 01/01/2023 - "In addition, cardiac fibrosis and hypertrophy were also mitigated via AT-001 treatment in mice with diabetic cardiomyopathy. " 01/01/2023 - "Inhibiting aldose reductase activity ameliorates diastolic dysfunction in mice with experimental type 2 diabetes, which may be due to the decline in myocardial fatty acid oxidation, indicating that treatment with AT-001 may be a novel approach to alleviate diabetic cardiomyopathy in patients with diabetes." 01/01/2023 - "Male C57BL/6J mice (8-week-old) were subjected to experimental type 2 diabetes/diabetic cardiomyopathy (high-fat diet [60% kcal from lard] for 10 weeks with a single intraperitoneal injection of streptozotocin (75 mg/kg) at 4 weeks), following which animals were randomized to treatment with either vehicle or AT-001, a next-generation aldose reductase inhibitor (40 mg/kg/day) for 3 weeks. "
5.	Heart Diseases (Heart Disease) 11/01/2021 - "In hospitalized patients with COVID-19 and co-morbid diabetes mellitus and heart disease, treatment with AT-001 was safe and well tolerated. " 11/01/2021 - "We conducted an open-label prospective phase 2 clinical trial to assess safety, tolerability and efficacy of AT-001 in patients hospitalized with COVID-19 infection, history of diabetes mellitus and chronic heart disease. "

Related Drugs and Biologics

1.	Aldehyde Reductase (Aldose Reductase)
2.	Fatty Acids (Saturated Fatty Acids)
3.	caficrestat
4.	Hypoxia-Inducible Factor 1
5.	Streptozocin (Streptozotocin)
6.	Relaxin
7.	Hormones (Hormone)
8.	Androgens
9.	Adrenal Cortex Hormones (Corticosteroids)
10.	Docetaxel (Taxotere)

Related Therapies and Procedures

1.	Therapeutics
2.	Intraperitoneal Injections
3.	Drug Therapy (Chemotherapy)